Propecia Lawsuits: The Lasting Effects of Delayed Drug Warnings.

Propecia lawsuits: the lasting effects of delayed drug warnings.

CMAJ. 2013 May 27;
Collier R

HubMed – drug


Luminescent complexes of terbium ion for molecular recognition of ibuprofen.

Luminescence. 2013 May 27;
Selivanova N, Vasilieva K, Galyametdinov Y

The complexation behavior and luminescent properties of terbium (Tb(3+) ) complexes containing bi-dental ligands were studied: nitrogen – 1,10-phenanthroline, and oxygen – trifluoroacetylacetone as well as acetylacetone ligands with ibuprofen (Ibu; a non-steroidal anti-inflammatory drug). Aqueous and aqueous alcohol microheterogeneous solutions were used as media. The effects of solubilization by various micellar solutions, pH and ligand type on luminescent properties of Tb(3+) complexes were investigated. Sensitized luminescence of mixed ligand complex Tb(1,10-phenanthroline)-Ibu and dynamic quenching effect in complex Tb(trifluoroacetylacetone)3 -Ibu allow Ibu determination with the limit of detection 5.3?×?10(-8) ?mol/L and 1.26?×?10(-6) ?mol/L, respectively. Copyright © 2013 John Wiley & Sons, Ltd. HubMed – drug


The Chennai declaration: A roadmap to tackle the challenge of antimicrobial resistance.

Indian J Cancer. 2013 Jan-Mar; 50(1): 71-3
Ghafur A, Mathai D, Muruganathan A, Jayalal JA, Kant R, Chaudhary D, Prabhash K, Abraham OC, Gopalakrishnan R, Ramasubramanian V, Shah SN, Pardeshi R, Huilgol A, Kapil A, Gill J, Singh S, Rissam HS, Todi S, Hegde BM, Parikh P

“A Roadmap to Tackle the Challenge of Antimicrobial Resistance – A Joint meeting of Medical Societies in India” was organized as a pre-conference symposium of the 2 nd annual conference of the Clinical Infectious Disease Society (CIDSCON 2012) at Chennai on 24 th August. This was the first ever meeting of medical societies in India on issue of tackling resistance, with a plan to formulate a road map to tackle the global challenge of antimicrobial resistance from the Indian perspective. We had representatives from most medical societies in India, eminent policy makers from both central and state governments, representatives of World Health Organization, National Accreditation Board of Hospitals, Medical Council of India, Drug Controller General of India, and Indian Council of Medical Research along with well-known dignitaries in the Indian medical field. The meeting was attended by a large gathering of health care professionals. The meeting consisted of plenary and interactive discussion sessions designed to seek experience and views from a large range of health care professionals and included six international experts who shared action plans in their respective regions. The intention was to gain a broad consensus and range of opinions to guide formation of the road map. The ethos of the meeting was very much not to look back but rather to look forward and make joint efforts to tackle the menace of antibiotic resistance. The Chennai Declaration will be submitted to all stake holders. HubMed – drug


Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.

Indian J Cancer. 2013 Jan-Mar; 50(1): 25-30
Joshi P, Patil V, Joshi A, Norohna V, Chaturvedi P, Chaukar D, Pai P, Nair D, Juvekar S, Agarwal JP, D’Cruz AK, Prabhash K

Objective: The aim of this retrospective study was to find out the role of neo-adjuvant chemotherapy (NACT) in changing the management and outcome of advanced hypopharyngeal cancer patients. Materials and Methods: This is a retrospective analysis of 59 treatment naïve, advanced hypopharyngeal cancer patients presenting to our tertiary care center from April 2010 to October 2011. NACT was given as two (platinum with taxane) or three drug with (platinum, taxane with 5-flurouracil [5 FU]) as 3 weekly regimen with cisplatin and docetaxel as 75 mg/m 2 each, 5-FU as 1000 mg/m 2 . NACT was either given with the intent of achieving: (1) surgical resection (extensive soft tissue disease, oropharyngeal involvement, extensive disease with cartilage erosion) or (2) organ preservation (Bulky disease with inner cartilage erosion, exolaryngeal disease without cartilage erosion, large N3 nodes). Results: The mean age of this population was 55 years. Most (83%) of the patients had pyriform sinus (PFS) involvement. 69% patients had Stage IVa disease, 21% Stage IVb and 10% Stage III. The overall response rate was 66%, including 06% complete responses and 60% partial responses. Following NACT, resectability was achieved in 30% (10/33) and organ preservation protocol was planned after NACT in 73% (19/26) patients. The main toxicities were neutropenia (grade 3, 4, 04%; febrile neutropenia, 4%), mucositis 5%, diarrhea 5%. The median progression free survival was 20 months. Conclusions: NACT can be useful in patients with oropharyngeal involvement to achieve surgical resection and larynx preservation in patients with bulky T3 disease. HubMed – drug